Pharmacologic targeting of oncogenic protein interactions remains the holy grail of developmental therapeutics research and holds promise to deliver a new era of treatments for human cancer. Whereas small molecule drug discovery continues to deliver effective agents for targeting deep, hydrophobic holes in protein targets such as kinase sites, the large, flat, and complex terrain that characterizes dynamic protein interaction surfaces remains largely undrugged. My work as a Senior Research Scientist in the Walensky laboratory and Linde Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute involves an alternative approach to dissecting and targeting cancer protein interactions using hydrocarbon-stapled peptides, which recapitulate the shape, stability, and bioactivity of natural ?-helical interaction motifs embedded within signaling proteins. Our research programs focus on generating stapled peptides to elucidate the functional binding surfaces and interaction mechanisms that drive the apoptotic blockades and pathologic transcriptional programs of human cancer, emphasizing deregulated BCL-2 family, p53, and KRAS signal transduction. We strive to continually broaden the utility of peptide stapling by adapting these novel reagents for proteomic discovery, structural analyses, cellular mechanism of action studies, and in vivo application. Through a series of collaborations, we have also deployed stapled peptides in diverse cancer contexts, studying and targeting oncogenic ?-catenin, EZH2/EED, Olig2, MUC1-C, ATF2, and RPA. In each of these projects, new mechanistic insights and prototype therapeutics have emerged. Our photoreactive stapled peptides designed for protein capture, rapidly identify and map binding sites on known and unanticipated protein targets, expanding the potentially druggable cancer proteome. Indeed, the clinical potential of stapled peptides as a new drug modality for cancer is reflected by ongoing clinical trials of the first dual inhibitor of HDM2/HDMX for reactivating p53 in advanced solid tumors and lymphomas (NCT02264613). Over the last ten years, I have led the stapled peptide synthesis facility of the Walensky laboratory and Linde Program in Cancer Chemical Biology. In doing so, I have been personally responsible for developing and optimizing the chemistry behind stapled peptide synthesis, and creating an integrated consultation, production, purification, quantitation, and characterization workflow that has fueled diverse applications and clinical translation of stapled peptides. My graduate training in chemistry, my postdoctoral work at the intersection of chemistry and cancer biology, and my numerous and multidisciplinary collaborative experiences as a Dana-Farber Research Scientist, underlie my tremendous enthusiasm for harnessing the potential of next-generation stapled peptides to impact both our understanding and treatment of human cancer.

Public Health Relevance

New chemical tools and drug modalities are urgently needed to dissect and target the pathologic protein interactions that drive human cancer. We synthesize and deploy hydrocarbon-stapled peptides, which recapitulate the shape, stability, and bioactivity of natural ?-helical interaction motifs, to interrogate the biochemistry, structural biology, proteomics, and cell biology of oncogenic proteins. By applying stapled peptides in a broad spectrum of cancer projects that span deregulated apoptosis, transcription, epigenetics, and cell migration, we are committed to advancing a new class of drugs for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Project #
5R50CA211399-05
Application #
9988206
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Luo, Ruibai
Project Start
2016-09-15
Project End
2021-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Stolte, Björn; Iniguez, Amanda Balboni; Dharia, Neekesh V et al. (2018) Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med 215:2137-2155
Harvey, Edward P; Seo, Hyuk-Soo; Guerra, Rachel M et al. (2018) Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor. Structure 26:153-160.e4
Escudero, Silvia; Zaganjor, Elma; Lee, Susan et al. (2018) Dynamic Regulation of Long-Chain Fatty Acid Oxidation by a Noncanonical Interaction between the MCL-1 BH3 Helix and VLCAD. Mol Cell 69:729-743.e7
Rezaei Araghi, Raheleh; Bird, Gregory H; Ryan, Jeremy A et al. (2018) Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells. Proc Natl Acad Sci U S A 115:E886-E895
Guerra, Rachel M; Bird, Gregory H; Harvey, Edward P et al. (2018) Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. Cell Rep 24:3393-3403.e5
Wachter, F; Morgan, A M; Godes, M et al. (2017) Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Oncogene 36:2184-2190
Pease-Raissi, Sarah E; Pazyra-Murphy, Maria F; Li, Yihang et al. (2017) Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration. Neuron 96:373-386.e6
Huhn, Annissa J; Guerra, Rachel M; Harvey, Edward P et al. (2016) Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. Cell Chem Biol 23:1123-1134